Literature DB >> 2896459

Sulfasalazine: II. Some notes on the discovery and development of salazopyrin.

N Svartz1.   

Abstract

In summing up: salazopyrin is an effective drug, particularly in ulcerative colitis. Serious adverse effects are remarkably rare. Salazopyrin provoked an improvement in 75-80% of cases of UC. It is excellently adapted for long-term treatment and, in this respect, is clearly superior to corticosteroids. It prevents relapses, particularly if the dosage is increased. The main indication for corticosteroids in UC is for acute attacks early in the course of the disease and to influence allergic symptoms during the disease. For acute swelling of the rectum, local treatment with corticosteroids or salazopyrin is often effective. Adverse effects occur in about 15% of cases treated with salazopyrin. They are due primarily to hypersensitivity to the drug. With very few exceptions, they disappear spontaneously or are controlled by corticosteroids or by some other treatment. The allergic pulmonary changes may give rise to a modest dyspnea, which is not fatal. The cyanotic and the yellow-coloring of the skin are harmless side effects. As to sulfa crystals in the kidneys and the urine, for the most part, they can be avoided by simple treatment. Agranulocytosis is a rare complication in the course of treatment with salazopyrin. During the 35 yr that the drug has been used, only 14 cases have been published in the literature. Of this number, three have died, but the treatment of the agranulocytosis is known in only one of them. Nonpublished cases probably exist, but this number does not seem to be great in my experience. In comparison with many other drugs (certain chemotherapeutics and antibiotics), the frequency of serious side effects caused by salazopyrin is remarkably low.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896459

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  18 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  Is mesalamine safe?

Authors:  Kenneth W Schroeder
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-11

Review 3.  Sulphasalazine in ulcerative colitis: in memoriam?

Authors:  J Hayllar; I Bjarnason
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

4.  Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers.

Authors:  C Rust; K Bauchmuller; C Bernt; T Vennegeerts; P Fickert; A Fuchsbichler; U Beuers
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

5.  Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.

Authors:  M N Aparicio-Pagés; H W Verspaget; J C Hafkenscheid; G E Crama-Bohbouth; A S Peña; I T Weterman; H W Lamers
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

Review 6.  Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.

Authors:  Ersilia M DeFilippis; Randy Longman; Michael Harbus; Kyle Dannenberg; Ellen J Scherl
Journal:  Curr Gastroenterol Rep       Date:  2016-03

Review 7.  Intestinal permeability, non-steroidal anti-inflammatory drug enteropathy and inflammatory bowel disease: an overview.

Authors:  I Bjarnason; T J Peters
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

8.  [Nanna Svartz (1890-1986) : The first female professor of medicine in Sweden].

Authors:  F A Wollheim
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

Review 9.  The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism.

Authors:  Peter Spanogiannopoulos; Elizabeth N Bess; Rachel N Carmody; Peter J Turnbaugh
Journal:  Nat Rev Microbiol       Date:  2016-03-14       Impact factor: 60.633

10.  Comparison between 5-aminosalicylic acid (5-ASA) and para-aminosalicylic acid (4-PAS) as potential protectors against Mn-induced neurotoxicity.

Authors:  Dinamene Santos; M Camila Batoreu; Michael Aschner; Ana P Marreilha dos Santos
Journal:  Biol Trace Elem Res       Date:  2013-01-15       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.